These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 26226206)

  • 1. Inflammatory targets of therapy in sickle cell disease.
    Owusu-Ansah A; Ihunnah CA; Walker AL; Ofori-Acquah SF
    Transl Res; 2016 Jan; 167(1):281-97. PubMed ID: 26226206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation in sickle cell disease.
    Conran N; Belcher JD
    Clin Hemorheol Microcirc; 2018; 68(2-3):263-299. PubMed ID: 29614637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
    Ansari J; Moufarrej YE; Pawlinski R; Gavins FNE
    Expert Rev Hematol; 2018 Jan; 11(1):45-55. PubMed ID: 29207881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for early investigational therapies for sickle cell disease.
    Conran N
    Expert Opin Investig Drugs; 2015 May; 24(5):595-602. PubMed ID: 25682977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling.
    Morrone K; Mitchell WB; Manwani D
    Semin Hematol; 2018 Apr; 55(2):68-75. PubMed ID: 30616808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Hematol Oncol Clin North Am; 2010 Feb; 24(1):199-214. PubMed ID: 20113903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
    Telen MJ
    Blood; 2016 Feb; 127(7):810-9. PubMed ID: 26758919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of miRNAs as Therapeutic Tools in Sickle Cell Disease.
    Cyrus C
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684143
    [No Abstract]   [Full Text] [Related]  

  • 13. cGMP modulation therapeutics for sickle cell disease.
    Conran N; Torres L
    Exp Biol Med (Maywood); 2019 Feb; 244(2):132-146. PubMed ID: 30691292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.
    Alramadhani D; Aljahdali AS; Abdulmalik O; Pierce BD; Safo MK
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies for sickle cell disease: towards a multi-agent approach.
    Telen MJ; Malik P; Vercellotti GM
    Nat Rev Drug Discov; 2019 Feb; 18(2):139-158. PubMed ID: 30514970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.